Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
21 nov. 2022 09h00 HE
|
Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
With 13% of CAGR, Neurological Biomarker Market to Gain $14+ Billion Revenue by 2027 | Exclusive Report by The Insight Partners
14 nov. 2022 06h58 HE
|
The Insight Partners
New York, Nov. 14, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Neurological Biomarker Market Size, Share, Growth, Trends and Forecast to 2027 – COVID-19 Impact and...
Parkinson's Disease Drug Market is Pegged to Reach $12.3 Billion By 2028 | Levodopa is the Most Popular Drug
07 nov. 2022 09h21 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford,USA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Parkinson's disease is a debilitating neurological disorder that affects millions of people worldwide. As the population ages, the number of people...
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
27 oct. 2022 07h00 HE
|
Amydis, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today...
Zhittya Genesis Medicine - Parkinson’s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment
25 oct. 2022 10h00 HE
|
Zhittya Genesis Medicine Inc
Invitation to a Free Luncheon Presentation in Jeddah, Saudi Arabia, on Monday, October 31, 2022, at 1:00 pm (13:00) View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients...
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
10 oct. 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the...
Global Neurological Biomarkers Market is Expected to Reach $18.9 Billion by 2031: Says AMR
27 sept. 2022 12h00 HE
|
Allied Market Research
Portland, OR, Sept. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Neurological Biomarkers Market size was estimated at $5.4 billion...
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
03 août 2022 17h30 HE
|
Aeterna Zentaris Inc
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE...
Zhittya Genesis Medicine announces: Free Zoom Webinar: Parkinson’s Disease Sufferers Motor Skills Improve by 50% After Medical Research Study
21 juin 2022 10h00 HE
|
Zhittya Genesis Medicine Inc
LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time...
Zhittya Genesis Medicine Announces: Parkinson’s Disease Sufferers Motor Skills Improved by 50% After Medical Research Study
16 juin 2022 14h00 HE
|
Zhittya Genesis Medicine Inc
LAS VEGAS, June 16, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that the human test subjects in its first-in-human research study for the...